Pfizer 2013 Annual Report Download - page 83

Download and view the complete annual report

Please find page 83 of the 2013 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 123

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
82
2013 Financial Report
Note 6. Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests
The following table provides the changes, net of tax, in Accumulated other comprehensive income/(loss):
Net Unrealized Gain/(Losses) Benefit Plans
(MILLIONS OF DOLLARS)
Foreign
Currency
Translation
Adjustments
Derivative
Financial
Instruments
Available-
For-Sale
Securities
Actuarial
Gains/
(Losses)
Prior Service
(Costs)/
Credits and
Other
Accumulated
Other
Comprehensive
Income/(Loss)
Balance, January 1, 2011 $ 169 $ (79) $ 28 $ (3,947) $ 389 $(3,440)
Other comprehensive income/(loss)(a) 775 (104)(160) (1,173) (27)(689)
Balance, December 31, 2011 944 (183)(132) (5,120) 362 (4,129)
Other comprehensive income/(loss)(a) (1,121) 22 368 (990)(103)(1,824)
Balance, December 31, 2012 (177)(161)236 (6,110) 259 (5,953)
Other comprehensive income/(loss)(a) (440)240 (86)2,887 54 2,655
Sale of 19.8% of subsidiary through an IPO(b) 27 — — — — 27
Balance, December 31, 2013 $ (590) $ 79 $ 150 $ (3,223) $ 313 $(3,271)
(a) Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $62 million loss in 2013, $7 million loss in 2012 and
$45 million loss in 2011.
(b) Relates to Zoetis (our former Animal Health subsidiary). See Note 2B. Acquisitions, Divestitures, Collaborative Arrangements and Equity-Method Investments:
Divestitures.
As of December 31, 2013, we estimate that we will reclassify into 2014 income the following pre-tax amounts currently held in Accumulated
other comprehensive loss: $48.0 million of unrealized holding losses on derivative financial instruments (expected to be offset by gains
resulting from reclassification adjustments related to available-for-sale securities); $195 million of actuarial losses related to benefit plan
obligations and plan assets and other benefit plan items; and $74 million of prior service credits, primarily related to benefit plan amendments.